The use of MPCs to promote growth of new blood vessels will have direct application for patients with peripheral arterial disease (PAD) who number more than eight million in the US alone. Risk factors for PAD are similar to those for coronary artery disease.

Thirty per cent of patients with existing PAD will ultimately require angioplasty to open the affected artery, and 10 per cent will require amputation of the affected limb within five to 10 years of diagnosis. Currently, there are more than 400,000 angioplasty procedures for PAD in the US. The number is expected to approach 640,000 by the end of 2005.

Angioblast plans to develop an MPC product for direct injection into the diseased artery at the time of angioplasty to increase the likelihood of long-term survival of the limb.

The Technology

• Overview
• Mesoblast Applications
  • Bone Repair
  • Cartilage Regeneration
  • Disc Regrowth
• Angioblast Applications
  • Heart Attack/Heart Failure
  • Peripheral Arterial Disease
  • Wound Ulcers
• Intellectual Property
• Glossary of Terms